\zaAlectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the Phase III ALEX study.
Peters S, Camidge R, Dziadziuszko R, Gadgeel S, Shaw AT, Kim DW, Pérol M, Rosell DR, Cheema P, Lim DW, Lin JJ, Pavlakis N, Ahn JS, Zhang L, Henschel V, Higgerson AA, McNally V, Rooney I, Scalori A, Smoljanovic V, Mok T.
Peters S, et al. Among authors: ahn js.
Ann Oncol. 2025 Oct 17:S0923-7534(25)04788-X. doi: 10.1016/j.annonc.2025.09.018. Online ahead of print.
Ann Oncol. 2025.
PMID: 41110693
Free article.